 Differentiation therapy acute promyelocytic leukemia tretinoin all-trans-retinoic acid BACKGROUND AND METHODS Patients acute promyelocytic leukemia characteristic translocation breakpoint chromosome region retinoic acid receptor-alpha RAR-alpha receptor growth differentiation myeloid cells vitro recent clinical studies tretinoin all-trans-retinoic acid complete remission patients acute promyelocytic leukemia effects tretinoin cellular maturation molecular abnormalities patients induction remission agent RESULTS Eleven patients acute promyelocytic leukemia tretinoin dose mg square meter body-surface area day Nine patients complete remission patients complete remission leukocytosis continued drug treatment Serial studies cellular morphologic features cell-surface immunophenotypic analysis fluorescence situ hybridization chromosome probe clinical response maturation leukemic clone patients treatment Northern blot analysis expression aberrant RAR-alpha patients complete remission expression abnormal RAR-alpha message detectable several patients complete morphologic cytogenetic remission CONCLUSIONS Tretinoin safe effective agent complete remission patients acute promyelocytic leukemia Clinical response agent leukemic-cell differentiation expression aberrant RAR-alpha nuclear receptor Molecular detection aberrant receptor useful marker residual leukemia patients disease